This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • High-dose alkylating chemotherapy in oligo-metasta...
Clinical trial

High-dose alkylating chemotherapy in oligo-metastatic breast cancer harboring homologous recombination deficiency

Read time: 1 mins
Last updated:9th May 2012
This study will investigates the effect of high dose alkylating chemotherapy compared to standard dose chemotherapy as part of a multimodality approach in patients with oligometastatic HRD positive or BRCA1/2 related breast cancer.
Category Value
Study start date 2012-05-09

View full details